Nasus Pharma Ltd.
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency… Read more
Market Cap & Net Worth: Nasus Pharma Ltd. (NSRX)
Nasus Pharma Ltd. (NYSE MKT:NSRX) has a market capitalization of $36.44 Million ($36.44 Million) as of March 18, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #27690 globally and #9266 in its home market, demonstrating a -36.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nasus Pharma Ltd.'s stock price $3.10 by its total outstanding shares 11755059 (11.76 Million).
Nasus Pharma Ltd. Market Cap History: 2025 to 2026
Nasus Pharma Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $107.56 Million to $36.44 Million (0.00% CAGR).
Nasus Pharma Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nasus Pharma Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NSRX by Market Capitalization
Companies near Nasus Pharma Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to Nasus Pharma Ltd. by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Nasus Pharma Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, Nasus Pharma Ltd.'s market cap moved from $107.56 Million to $ 36.44 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $36.44 Million | -66.12% |
| 2025 | $107.56 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Nasus Pharma Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.44 Million USD |
| MoneyControl | $36.44 Million USD |
| MarketWatch | $36.44 Million USD |
| marketcap.company | $36.44 Million USD |
| Reuters | $36.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.